Abstract
Metabolic syndrome is a major global threat nowadays due to urbanization, sedentary life style and increased incidence of obesity. FGF-19 has recently been introduced as a novel marker regulating metabolism, reversing diabetes mellitus, hyper lipidemia, hepatic steatosis and adiposity. Aim & Objective: To compare the serum Fibroblast Growth Factor 19 levels of metabolic syndrome patients with healthy individuals. To analyze the correlation between serum FGF 19 and the components of metabolic syndrome. Materials & Methods: A total of 50 patients and 50 controls were included in the study. After obtaining informed consent, anthropometric measures (Height, Weight, BMI & Waist circumference) were taken. Blood investigations such as FGF 19, TC, HDL-cholesterol were estimated and LDL, VLDL & AIP levels were calculated. Statistical Analysis: Student’s t-test was employed for the statistical analysis and data were expressed in terms of mean and standard deviation. ‘p’ value less than 0.05 is considered as statistically significant. Correlation between the measured parameters was assessed using Pearson’s correlation coefficient. Result & Conclusion: Serum levels of FGF 19 were low in patients with metabolic syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
